Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 6/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | IDH2 | P48735 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31038939 | 0.77 | GABRA1 (0.50) | ADRB1TAS2R14PKMLOXL2SYK | |
| SCHEMBL17959 | 0.77 | GABRA1 (0.50) | ADRB1TAS2R14PKMLOXL2SYK | |
| SCHEMBL27285543 | 0.74 | ADRB1 (0.44) | ADRB1TAS2R14PKMLOXL2SYK | |
| SCHEMBL3295825 | 0.74 | MALT1 (0.47) | ADRB1TAS2R14PKMLOXL2SYK | |
| SCHEMBL482717 | 0.73 | TRPV4 (0.45) | ADRB1TAS2R14PKMLOXL2SYK | |
| SCHEMBL1968808 | 0.73 | ADRB1 (0.43) | ADRB1TAS2R14PKMLOXL2SYK | |
| SCHEMBL2873952 | 0.73 | ADRB1 (0.43) | ADRB1TAS2R14PKMLOXL2SYK | |
| SCHEMBL1337601 | 0.73 | ADRB1 (0.43) | ADRB1TAS2R14PKMLOXL2SYK | |
| SCHEMBL17049228 | 0.73 | ADRB1 (0.43) | ADRB1TAS2R14PKMLOXL2SYK | |
| SCHEMBL14625676 | 0.73 | ADRB1 (0.43) | ADRB1TAS2R14PKMLOXL2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170079954-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2017-03-23 | — | — | US | claimed |
| US-9540351-B2 | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | claimed |
| EP-3046918-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | Axikin Pharmaceuticals, Inc. (US) | 2016-07-27 | — | — | EP | claimed |
| US-9382237-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | claimed |
| US-9365556-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-06-14 | — | — | US | claimed |
| US-9346792-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-05-24 | — | — | US | claimed |
| US-20150105389-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | claimed |
| EP-2852586-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | Axikin Pharmaceuticals, Inc. (US) | 2015-04-01 | — | — | EP | claimed |
| WO-2015042111-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-03-26 | — | — | WO | claimed |
| US-20150080397-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2015-03-19 | — | — | US | claimed |
| US-20150080398-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2015-03-19 | — | — | US | claimed |
| EP-2834232-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | Axikin Pharmaceuticals, Inc. (US) | 2015-02-11 | — | — | EP | claimed |
| US-8916555-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-12-23 | — | — | US | claimed |
| US-20130303492-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2013-11-14 | — | — | US | claimed |
| US-20130274227-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-10-17 | — | — | US | claimed |
| WO-2013138617-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | WO | claimed |
| WO-2013138613-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | WO | claimed |
| US-20060089371-A1 | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | BAYER HEALTHCARE AG (DE) | 2006-04-27 | — | — | US | claimed |
| EP-1575919-A1 | PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST | Bayer HealthCare AG (DE) | 2005-09-21 | — | — | EP | claimed |
| WO-2004043926-A1 | PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST | BAYER HEALTHCARE AG (DE) | 2004-05-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274227-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, MAP3K1 | ADRB1 1551/4885TAS2R14 3750/4885PKM 316/4885 |
| US-20170079954-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | GRK3, DMPK, PRKAG3 | ADRB1 981/4885TAS2R14 2212/4885PKM 212/4885 |
| US-20150080398-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, MAP3K1 | ADRB1 1551/4885TAS2R14 3750/4885PKM 316/4885 |
| US-20150105389-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, MAP3K1 | ADRB1 1551/4885TAS2R14 3750/4885PKM 316/4885 |
| US-20150080397-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | GRK3, DMPK, PRKAG3 | ADRB1 981/4885TAS2R14 2212/4885PKM 212/4885 |
| US-20130303492-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, MAP3K1 | ADRB1 1551/4885TAS2R14 3750/4885PKM 316/4885 |
| US-20060089371-A1 | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | BPHL, HRH4, HRH2 | ADRB1 28/4885TAS2R14 1099/4885PKM 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.